Label

Title

Subtext

Products Intro
Close Video
Board member Audit & Risk Corporate Administration & Transactions Corporate Responsibility Nominations & Corporate Governance Remuneration Science Chairs'
Sir Jonathan Symonds   Member   Chair     Chair
Emma Walmsley   Member          
Julie Brown   Member          
Elizabeth McKee Anderson Member Member     Member    
Charles Bancroft Chair Member   Member Member   Member
Dr Hal Barron   Member       Member  
Dr Anne Beal   Member Chair Member Member   Member
Dr Hal Dietz   Member       Chair Member
Dr Jesse Goodman   Member Member     Member  
Urs Rohner Member Member   Member Chair   Member
Dr Vishal Sikka   Member Member        

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

Transcript1

Transcript1

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Advances in science and medicine means that remission is already considered to be an accepted treatment goal in many other immune-mediated conditions, such as rheumatoid arthritis, and eosinophilic granulomatosis with polyangiitis (EGPA).

These conditions have a common link: a dysfunction in the immune system that gives rise to overactivity and excessive inflammation, causing it to attack the body as if it were a threat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus sodales, justo eu mattis egestas, nibh mauris interdum turpis, eu facilisis arcu dui congue risus. cursus scelerisque metus

Click here

 

Culture module header

Culture module sub header

Button title

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

Modal title

alt text
text
Sometimes back, I needed to count characters in a piece of content for use as an informational post

Modal 2

RTE 2

modal title

Science Thing alt
text
Sometimes back, I needed to count characters in a piece of content for use as an informational post

Modal 3

RTE 3

pinch icon pinch icon

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

Heading

TItle
0:00

TItle

description

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

Title 2
0:00

Title 2
Title 3
0:00

Title 3
Title 4
0:00

Title 4
Title 5
0:00

Title 5

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec gravida nulla nec lorem pulvinar molestie. Proin a tempus augue. Donec euismod eros dictum diam luctus gravida. Duis dapibus vel tellus vitae tincidunt. Nam massa turpis, malesuada eu dignissim et, iaculis id ligula. Sed ut diam at sem molestie auctor. Mauris non mollis lacus.

 

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec gravida nulla nec lorem pulvinar molestie.

Happy Fella

Quote name

Job title

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

Test alt text heading

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

Full width text & image

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

Alt text for bg image
Sometimes back, I needed to count characters in a piece of content for use as an informational post

Full width single large promo

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

Content highlight module

alt text long img

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

Large cards with modal

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

Content modals

  • Modal 1

    • Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

    Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

    People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

    Click here

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

alt text

Quotee

Quotee subtext

Cards Pop up

tratada 11

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

Announcement Carousel

Alt text for bg image

tag

title

en-gb

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

Click here

01:00

tag

title

23-06-14